European Union: The Proposed Regulation on Medicines for Paediatric Use

Last Updated: 22 February 2006
Article by Stella Wong

The Council of Ministers (made up of representatives of Member States) has backed the proposed EU Regulation1 on medicines for children. The draft Regulation can now proceed to the second reading in the European Parliament and could become law by 2007. The Regulation aims to improve the health and safety of children in Europe by increasing the research, development and authorisation of medicines for use in children. It is hoped that this will be achieved without subjecting children to unnecessary clinical trials.

There are 100 million children in the 25 Member States of the European Union. This represents over 20% of the EU population. Whilst medicines authorised for use in adults must undergo extensive testing, including clinical trials, to ensure that they are safe, of high quality and effective, this is not the case for medicines used to treat children in Europe. It has been shown that more than 50% of medicines used in children have not been tested and are not authorised for use in children. In practice, this means that when a doctor prescribes for a child, the decision to use a particular medicine at a certain dose is not evidence- based. This is relevant since the paediatric population has age-related differences to drug handling and side effects; this may lead to under or over dosing and an increase in adverse effects. In addition the doctor is limited in what can be prescribed since there are practical problems of administration; a child may not be able to swallow a tablet and obtaining the right dose using an adult formulation can be difficult.

Currently the pharmaceutical industry is free to choose which medicines to develop, authorise and market. Their choices are driven by the predicted overall return on investment, which is dependent on the size of the target market and the price achievable within the market-place. Unfortunately, children are not as lucrative as adults in this respect, since the number of children suffering specific diseases is generally lower than in the adult population. Additionally, studies in the paediatric population are more complex due to the wide variation within the population; from a premature baby to a 15 year old. Market forces alone have proved insufficient to stimulate adequate research into medicines for children, since the potential return is considered insufficient to justify such investment into research and development.

The draft Regulation aims to address the issues of the lack of research and authorised medicines for use in children.

The key elements are:


  • A Paediatric Investigation Plan ("PIP"). This is the research and development programme aimed at ensuring the necessary data are generated in order to authorise the medicine for use in children. Two principles need to be applied when drawing up this plan, first, the study should only be conducted if there is a potential therapeutic benefit to children, and secondly, the requirements for studies in children should not delay the authorisation of medicines for adults.
  • The data resulting from the agreed PIP will be required at the time of the marketing authorisation application.

A system of waivers from the Requirement for a PIP and the resulting data will exist for medicines that are unlikely to benefit children; mainly medicines that have been developed for diseases that occur only in adults, such as Alzheimers disease. In addition, there will be a system of deferrals from the Requirement for data, to ensure medicines are tested in children only when it is safe to do so and to prevent the delay of authorisation of medicines for adults.


  • As compensation for the extra costs involved in conducting clinical trials before authorisation of drugs and as an incentive for more research and development, companies will be granted a six month extension of their patent in the form of a six month extension to the Supplementary Protection Certificate ("SPC").
  • For orphan medicines the incentive will be an additional two years of market exclusivity to the existing ten years awarded under the EU Orphan Regulations. Orphan medicines are those intended for rare and life threatening diseases or medicines that are unlikely to be developed under normal market conditions.


  • The draft Regulation creates a Paediatric Committee, which will assess the PIPs and waiver or defer the Requirements where necessary.
  • The creation of a fund to finance research into the possible adaptation of medicines used in adults for use by children.
  • The setting up of a network of researchers and research centres designed to prevent duplication of research and tests on children.

The draft Regulation has come under attack from various fields. Poland voted against the draft Regulation as it disagreed with the fixed six month extension to the SPC, arguing that this delayed the marketing of cheaper generic products, thereby restricting patients’ access to therapies and increasing expenditure in national healthcare budgets. Poland’s objections will not prevent the adoption of the Regulation. Latvia also expressed concerns about the SPC extension although it voted in favour of the Regulation. The European Generic Medicines Association has argued that the six month extension should only apply to low selling products and not to blockbusters, since this would generate up to two billion Euros per year in additional costs to healthcare systems. The European Union Geriatric Medicine Society has pointed out that the number of people aged over 80 years is set to double every ten years, yet the majority of medicines given to older people have not been studied in clinical trials in older populations.

Clearly there are a number of issues to consider:

  • whilst the Requirements have been deemed necessary since market forces alone have failed to stimulate sufficient research, there must be a cost-benefit balance such that the incentive is adequate to stimulate research but not excessive. A disproportionately high reward could stimulate research for the wrong motive;
  • the reward/incentive must strike a balance between the gain for the innovative industry and the potential costs to society; the burden on the healthcare system and the costs to the generic industry. By extending patent life, generic competition will be delayed. The potential public health benefits of having safe and effective medicines for children is thought to justify the loss of profit to the generics sector and the increase in costs to the healthcare system; and finally
  • perhaps the Paediatric Committee should target research by considering the existing evidence on factors such as adverse outcomes from the use of certain medicines. This could avoid studies into medicines where there is no problem.


1 Proposal for a Regulation on medicinal products for paediatric use and amending Regulation (EEC) No.1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No.726/2004. The Common Position was adopted by the Council on 17 February 2006.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.